Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
文献类型：期刊论文
| 作者 | Zhu, Motao1; Ding, Xilai1; Zhao, Ruifang1,2; Liu, Xuewu3; Shen, Haifa3; Cai, Chunmei1; Ferrari, Mauro3; Wang, Helen Y.1; Wang, Rong-Fu1 |
| 刊名 | Journal of controlled release
 |
| 出版日期 | 2018-02-28 |
| 卷号 | 272页码:72-82 |
| 关键词 | Cancer vaccine Mesoporous silicon microparticles Melanoma immunotherapy Dual tlr signaling Trp2 peptide |
| ISSN号 | 0168-3659 |
| DOI | 10.1016/j.jconrel.2018.01.004 |
| 通讯作者 | Wang, rong-fu(rwang3@houstonmethodist.org) |
| 英文摘要 | Despite the importance and promise of cancer vaccines for broader prevention and treatment of cancer, limited clinical responses are observed, suggesting that key rational designs are required for inducing potent immune responses against cancer. here we report a mesoporous silicon vector (msv) as a multi-functional microparticle for formulating an efficient cancer vaccine composed of b16 melanoma derived-tyrosinase related protein 2 (trp2) peptide and dual toll-like receptor (tlr) agonists. we demonstrated that msv microparticles protected the peptide from rapid degradation for prolonged antigen presentation to immune cells. moreover, msv enabled co-delivery of two different tlr agonists [cpg oligonucleotide and monophosphoryl lipid a (mpla)] along with trp2 peptide into the same dendritic cell (dc), thus increasing the efficiency and capacity of dcs to induce potent trp2-specifc cd8(+) t cell responses against b16 melanoma. furthermore, this msv-based dc vaccine could significantly prolong the median survival of tumor-bearing mice by orchestrating effective host immune responses involving cd8(+) t cells, cd4(+) t cells and macrophages. our study provides rational and potentially translational approach to develop durable and potent immunotherapy for patients with cancer by delivering various combinations of tumor antigens, neoantigens and innate immune agonists. |
| WOS关键词 | CD4(+) T-CELLS ; CANCER-IMMUNOTHERAPY ; INNATE IMMUNITY ; ANTITUMOR IMMUNITY ; CROSS-PRESENTATION ; VACCINE ADJUVANTS ; DRUG-DELIVERY ; RNA DELIVERY ; NANOPARTICLES ; MIGRATION |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| WOS类目 | Chemistry, Multidisciplinary ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000425380700008 |
| 出版者 | ELSEVIER SCIENCE BV |
| URI标识 | http://www.irgrid.ac.cn/handle/1471x/2178049 |
| 专题 | 高能物理研究所 |
| 通讯作者 | Wang, Rong-Fu |
| 作者单位 | 1.Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA 2.Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China 3.Houston Methodist Res Inst, Dept Nanomed, Houston, TX 77030 USA |
| 推荐引用方式 GB/T 7714 | Zhu, Motao,Ding, Xilai,Zhao, Ruifang,et al. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma[J]. Journal of controlled release,2018,272:72-82. |
| APA | Zhu, Motao.,Ding, Xilai.,Zhao, Ruifang.,Liu, Xuewu.,Shen, Haifa.,...&Wang, Rong-Fu.(2018).Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.Journal of controlled release,272,72-82. |
| MLA | Zhu, Motao,et al."Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma".Journal of controlled release 272(2018):72-82. |
入库方式： iSwitch采集
来源：高能物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。